Yingwen  Zhang

Dr. Yingwen Zhang


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Aging and disease
Verified
Journal Article
Open access
CYChao-Chao Yu
Chao-Chao Yu
YDYan-Jun Du
Yan-Jun Du
JLJin Li
Jin Li
YLYi Li
Yi Li
LWLi Wang
Li Wang
YZYingwen Zhang
Yingwen Zhang
Due to global population aging and modern lifestyle changes, the incidence of central nervous system (CNS) disorders, such as neurodegenerative diseases, neuropsychiatric disorders, and cerebrovascular diseases, is increasing and has become a major public health challenge. Current medications commonly used in the clinic are far from satisfactory and may cause serious side effects. Therefore, the identification of novel drugs for the effective management of CNS diseases is very urgent. Puerarin, a highly bioactive ingredient isolated from Pueraria lobata, is known to possess a broad spectrum of pharmacological properties including anti-diabetic, anti-inflammatory, anti-antioxidant, neuroprotective, and cardioprotective features. However, its clinical application is limited due to its poor water solubility. Since puerarin has demonstrated a wide range of neuroprotective functions in various CNS diseases, such as Alzheimer’s disease, Parkinson’s disease, cerebral ischemia, depression, and spinal cord injury, it has been attracting increasingly intense attention worldwide. In this review, we intend to extensively summarize the research progress on neuroprotective mechanisms of puerarin in recent years and discuss the future directions of its application in CNS disease treatment.

1 January 2021 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
HKHaoliang Ke
Haoliang Ke
XWXiuping Wang
Xiuping Wang
ZZZhen Zhou
Zhen Zhou
WAWang Ai
Wang Ai
ZWZhaoyan Wu
Zhaoyan Wu
YZYingwen Zhang
Yingwen Zhang

4 December 2017 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
CWChaoyan Wu
Chaoyan Wu
YKYuan Ke
Yuan Ke
YZYi-Fei Zeng
Yi-Fei Zeng
YZYingwen Zhang
Yingwen Zhang
HYHaijun Yu
Haijun Yu
We have reported that Chinese herbs Astragalus polysaccharide (APS) can inhibit nuclear factor kappaB (NF-κB) activity during the development of diabetic nephropathy in mice. NF-κB plays important roles in genesis, growth, development and metastasis of cancer. NF-κB is also involved in the development of treatment resistance in tumors. Here we investigated the antitumor activity of APS in human non-small cell lung cells (A549 and NCI-H358) and the related mechanisms of action. The dose–effect and time-effect of antitumor of APS were determined in human lung cancer cell line A549 and NCI-H358. The inhibition effect of APS on the P65 mRNA and protein was detected by reverse transcriptase-PCR (RT-PCR) and Western blot in A549 cells respectively. The inhibition effect of APS on the p50, CyclinD1 and Bcl-xL protein was detected by Western blot in A549 cells respectively. The effect of APS on NF-κB transcription activity was measured with NF-κB luciferase detection. Finally, the nude mice A549 xenograft was introduced to confirm the antitumor activity of APS in vivo. Cell viability detection results indicated that APS can inhibit the proliferation of human lung cancer cell line A549 and NCI-H358 in the concentration of 20 and 40 mg/mL. NF-κB activator Phorbol 12-myristate13-acetate (PMA) can attenuate the antitumor activity of APS in both cell lines, but NF-κB inhibitor BAY 11-7082 (Bay) can enhance the effect of APS in both cell lines. In vivo APS can delay the growth of A549 xenograft in BALB/C nude mice. APS can down-regulate the expression of P65 mRNA and protein of A549 cells and decrease the expression of p50, CyclinD1 and Bcl-xL protein. The luciferase detection showed that the APS could reduce the P65 transcription activity in A549 cells. PMA can partially alleviate the inhibition activity of P65 transcription activity of APS in A549 cells, and Bay can enhance the down-regulation of the P65 transcription activity induced by APS in A549 cells. APS has a significant antitumor activity in human lung cancer cells A549 and NCI-H358. NF-κB inhibition may mediate the antitumor effect.

9 July 2022 in Journal of Zhejiang University-SCIENCE B
Verified
Journal Article
Closed access
PDF file
CYChaochao Yu
Chaochao Yu
YLYi Li
Yi Li
GCGuopeng Chen
Guopeng Chen
CWChaoyan Wu
Chaoyan Wu
XWXiuping Wang
Xiuping Wang
YZYingwen Zhang
Yingwen Zhang
Breast cancer is globally the most common invasive cancer in women and remains one of the leading causes of cancer-related deaths. Surgery, radiotherapy, c

1 December 2018 in Diabetes Research and Clinical Practice
Verified
Journal Article
Closed access
YZYingwen Zhang
Yingwen Zhang
XWXiuping Wang
Xiuping Wang
XRXiaodan Ren
Xiaodan Ren
MZManling Zhang
Manling Zhang

27 January 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
CYChao-Chao Yu
Chao-Chao Yu
YLYi Li
Yi Li
ZCZhao-Jun Cheng
Zhao-Jun Cheng
XWXi Wang
Xi Wang
WMWei Mao
Wei Mao
YZYingwen Zhang
Yingwen Zhang
Multiple myeloma (MM) is a hematological malignancy characterized by clonal expansion of plasma cells in bone marrow, leading to the overproduction of monoclonal immunoglobulins. The clinical manifestations resulting from monoclonal proteins and malignant cells include signs of end-organ damage, such as hypercalcemia, renal failure, anemia, and bone lesions. Despite improvement in the survival of MM patients with use of myeloma-targeted and immunomodulatory therapies, MM remains an incurable disease. Moreover, patients with relapsed or refractory MM show poor survival outcomes. In recent years, there has been a growing interest in the use of traditional Chinese medicinal materials (TCMMs) for management of a wide spectrum of diseases. The bioactive ingredients derived from TCMMs hold great potential for the development of anticancer drugs. Here we summarize the evidence of the pharmacological effects of the active components in TCMMs on MM, including curcumin, resveratrol, baicalein, berberine, bufalin, cinobufagin, gambogic acid, ginsenoside, icariin, daidzin, formononetin, polysaccharides extracts from Hedyotis difus, and scutellarein. Available evidence indicates that the anti-MM effects of these bioactive ingredients are mediated via regulation of proliferation, apoptosis, autophagy, cell cycle, osteogenic differentiation, and drug resistance. In the future, the underlying mechanisms of the anti-MM effects of these components should be further investigated. Large-scale and well-designed clinical trials are also required to validate the efficacy of these bioactive constituents for MM.